[go: up one dir, main page]

JP2017504328A - 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物 - Google Patents

二重特異性ｃｄ３及びｃｄ１９抗原結合構築物 Download PDF

Info

Publication number
JP2017504328A
JP2017504328A JP2016546800A JP2016546800A JP2017504328A JP 2017504328 A JP2017504328 A JP 2017504328A JP 2016546800 A JP2016546800 A JP 2016546800A JP 2016546800 A JP2016546800 A JP 2016546800A JP 2017504328 A JP2017504328 A JP 2017504328A
Authority
JP
Japan
Prior art keywords
antigen
scfv
polypeptide
binding construct
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546800A
Other languages
English (en)
Japanese (ja)
Inventor
ゴードン イウ コン エング
ゴードン イウ コン エング
フォン クロイデンシュタイン トマス スプレッター
フォン クロイデンシュタイン トマス スプレッター
レオナード ジー． プレスタ
レオナード ジー． プレスタ
Original Assignee
ザイムワークス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/046436 external-priority patent/WO2015006749A2/en
Application filed by ザイムワークス，インコーポレイテッド filed Critical ザイムワークス，インコーポレイテッド
Publication of JP2017504328A publication Critical patent/JP2017504328A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2016546800A 2014-01-15 2015-01-15 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物 Pending JP2017504328A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461927877P 2014-01-15 2014-01-15
US61/927,877 2014-01-15
US201461978719P 2014-04-11 2014-04-11
US61/978,719 2014-04-11
USPCT/US2014/046436 2014-07-11
PCT/US2014/046436 WO2015006749A2 (en) 2013-07-12 2014-07-11 Bispecific cd3 and cd19 antigen binding contructs
US201462025932P 2014-07-17 2014-07-17
US62/025,932 2014-07-17
PCT/US2015/011664 WO2015109131A2 (en) 2014-01-15 2015-01-15 Bi-specific cd3 and cd19 antigen-binding constructs

Publications (1)

Publication Number Publication Date
JP2017504328A true JP2017504328A (ja) 2017-02-09

Family

ID=53543619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546800A Pending JP2017504328A (ja) 2014-01-15 2015-01-15 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物

Country Status (11)

Country Link
US (1) US20160326249A1 (es)
EP (1) EP3094737A4 (es)
JP (1) JP2017504328A (es)
KR (1) KR20160107304A (es)
CN (1) CN106062206A (es)
AU (1) AU2015206407A1 (es)
BR (1) BR112016016114A2 (es)
CA (1) CA2936785A1 (es)
MX (1) MX2016009050A (es)
RU (1) RU2016132863A (es)
WO (1) WO2015109131A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513383A (ja) * 2019-03-19 2022-02-07 益科思特（北京）医葯科技▲發▼展有限公司 二重特異性抗体及びその作製方法と使用
JP2022544760A (ja) * 2019-08-15 2022-10-21 ヤンセン バイオテツク，インコーポレーテツド 改善された単鎖可変断片のための材料及び方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137706A (zh) * 2015-07-15 2018-06-08 酵活有限公司 药物缀合的双特异性抗原结合构建体
EP3556772A4 (en) * 2016-12-13 2020-09-09 Carsgen Therapeutics Ltd HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
WO2018199593A1 (ko) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체
WO2018213848A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
WO2018217947A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CA3072575A1 (en) 2017-08-11 2019-02-14 City Of Hope Rna aptamers against transferrin receptor (tfr)
CN112040971A (zh) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CN110305217B (zh) 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
SG11202010064QA (en) * 2018-04-13 2020-11-27 Affimed Gmbh Nk cell engaging antibody fusion constructs
CN108490174B (zh) * 2018-04-18 2022-06-24 上海尚珞生物医药科技有限公司 检测car-t细胞的方法及其应用
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
US20200109200A1 (en) * 2018-10-09 2020-04-09 Genentech, Inc. Methods and systems for determining synapse formation
KR20210099614A (ko) * 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
EP3953385A4 (en) * 2019-04-08 2022-12-21 Memorial Sloan Kettering Cancer Center CD19 ANTIBODIES AND METHODS OF USE THEREOF
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
CN114641307A (zh) * 2019-08-19 2022-06-17 艾佩斯瑞生物制药公司 抗cd19抗体及其用途
CN113493518B (zh) * 2020-04-02 2024-04-19 重庆精准生物技术有限公司 优化的连接肽组合及其应用
EP4139347A4 (en) * 2020-04-24 2024-06-05 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
US20230272052A1 (en) * 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
EP4240491A1 (en) * 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
US20250041341A1 (en) * 2021-12-20 2025-02-06 Baylor College Of Medicine Polypeptides targeting cd105+ cancers
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024048490A1 (ja) 2022-08-29 2024-03-07 第一三共株式会社 変異Ｆｃ領域を含む抗体薬物コンジュゲート
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
HUE029257T2 (en) * 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and their use
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012332021B8 (en) * 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2014012085A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
AU2014287011A1 (en) * 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513383A (ja) * 2019-03-19 2022-02-07 益科思特（北京）医葯科技▲發▼展有限公司 二重特異性抗体及びその作製方法と使用
JP7262597B2 (ja) 2019-03-19 2023-04-21 益科思特（北京）医葯科技▲發▼展有限公司 二重特異性抗体及びその作製方法と使用
JP2022544760A (ja) * 2019-08-15 2022-10-21 ヤンセン バイオテツク，インコーポレーテツド 改善された単鎖可変断片のための材料及び方法
JP7797373B2 (ja) 2019-08-15 2026-01-13 ヤンセン バイオテツク，インコーポレーテツド 改善された単鎖可変断片のための材料及び方法

Also Published As

Publication number Publication date
CN106062206A (zh) 2016-10-26
KR20160107304A (ko) 2016-09-13
WO2015109131A2 (en) 2015-07-23
EP3094737A2 (en) 2016-11-23
BR112016016114A2 (pt) 2018-05-22
RU2016132863A (ru) 2018-02-20
US20160326249A1 (en) 2016-11-10
WO2015109131A3 (en) 2015-11-12
AU2015206407A1 (en) 2016-08-18
CA2936785A1 (en) 2015-07-23
EP3094737A4 (en) 2017-08-09
MX2016009050A (es) 2016-12-09

Similar Documents

Publication Publication Date Title
JP2017504328A (ja) 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
US20220135676A1 (en) Multispecific antigen binding proteins
JP6708635B2 (ja) ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
US11021694B2 (en) SIRP-α immunoglobulin fusion proteins
TWI832824B (zh) 自單特異性抗體於活體內產生多特異性抗體之方法
JP2021072784A (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
TW202204409A (zh) Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
JP2019513777A (ja) 免疫療法薬を標的とする多重特異性抗原結合構築物
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
US20200048371A1 (en) Tumor antigen presentation inducer constructs and uses thereof
CN107428830A (zh) 单体fc结构域
WO2024131962A1 (zh) 新型抗gprc5d抗体
JP2024507937A (ja) Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体
US20200181288A1 (en) Cell engaging binding molecules
TW202016144A (zh) 包括cd3抗原結合片段之組成物及其用途
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
JP2022540904A (ja) ヒトｔｒｅｍ－１に対する抗体およびその使用
US20250011422A1 (en) Siglec-6 antibodies, derivative compounds and related uses
WO2025083273A1 (en) Binding molecules
CN119546636A (zh) FcRn-结合多肽及其用途
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161025